Harvard Bioscience (HBIO) Stock Price, News & Analysis

Company Overview

Harvard Bioscience, Inc. develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company’s product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics.

Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools. The company serves its customers via direct sales and an extensive distributor network, with significant operations in North America, Europe and the Asia‐Pacific region.

Founded in 1901 and headquartered in Holliston, Massachusetts, Harvard Bioscience has grown through organic innovation and strategic acquisitions to support the evolving needs of life science research. The company maintains manufacturing and R&D facilities in the United States and Europe and is managed by an experienced team of professionals with backgrounds in engineering, sales and scientific product development.

Key Stats

• Today's Range: $0.47 to $0.49
• 50-Day Range: $0.40 to $0.57
• 52-Week Range: $0.28 to $2.92
• Volume: 681,344 shs
• Average Volume: 1.06 million shs
• Market Capitalization: $21.52 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.00
• Consensus Rating: Moderate Buy

Harvard Bioscience Stock Analysis - MarketRank™

Harvard Bioscience scored higher than 80% of companies evaluated by MarketBeat, and ranked 197th out of 667 stocks in the computer and technology sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Harvard Bioscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Upside Potential

Harvard Bioscience has a consensus price target of $2.00, representing about 313.8% upside from its current price of $0.48.

Amount of Analyst Coverage

Harvard Bioscience has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Harvard Bioscience is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Harvard Bioscience is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Harvard Bioscience has a P/B Ratio of 0.33. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.00% of the float of Harvard Bioscience has been sold short.

Short Interest Ratio / Days to Cover

Harvard Bioscience has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Harvard Bioscience has recently increased by 27.88%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Harvard Bioscience does not currently pay a dividend.

Dividend Growth

Harvard Bioscience does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.5 / 5
• Environmental Score: -1.14

Percentage of Shares Shorted

2.00% of the float of Harvard Bioscience has been sold short.

Short Interest Ratio / Days to Cover

Harvard Bioscience has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Harvard Bioscience has recently increased by 27.88%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.35

News Sentiment

Harvard Bioscience has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Computer and Technology companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Harvard Bioscience this week, compared to 15 articles on an average week.

Search Interest

5 people have searched for HBIO on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Harvard Bioscience to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Harvard Bioscience insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.50% of the stock of Harvard Bioscience is held by insiders.

Percentage Held by Institutions

80.87% of the stock of Harvard Bioscience is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

HBIO Stock Analysis - Frequently Asked Questions

How have HBIO shares performed this year?

Harvard Bioscience's stock was trading at $2.11 on January 1st, 2025. Since then, HBIO stock has decreased by 77.1% and is now trading at $0.4833.

How were Harvard Bioscience's earnings last quarter?

Harvard Bioscience, Inc. (NASDAQ:HBIO) issued its quarterly earnings results on Tuesday, November, 2nd. The medical instruments supplier reported $0.06 EPS for the quarter, meeting analysts' consensus estimates of $0.06. The medical instruments supplier had revenue of $29.66 million for the quarter, compared to analysts' expectations of $28.10 million. Harvard Bioscience had a negative net margin of 64.68% and a negative trailing twelve-month return on equity of 5.64%.

Does Harvard Bioscience have any subsidiaries?

Harvard Bioscience subsidiaries include these companies: Data Sciences International.

Who are Harvard Bioscience's major shareholders?

Harvard Bioscience's top institutional investors include AMH Equity Ltd (7.94%), Harvey Partners LLC (4.81%), Geode Capital Management LLC (1.00%) and Pasadena Private Wealth LLC (0.55%).
View institutional ownership trends.

How do I buy shares of Harvard Bioscience?

Shares of HBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Harvard Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Harvard Bioscience investors own include YETI (YETI), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), Alphabet (GOOG), Stag Industrial (STAG) and Tesla (TSLA).

Company Calendar

• Last Earnings: 11/02/2021
• Today: 9/18/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Computer and Technology
• Industry: INSTRU - SCIENTFC
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:HBIO
• CIK: 1123494
• Web: www.harvardbioscience.com
• Phone: (508) 893-8999
• Fax: 508-429-5732
• Employees: 490
• Year Founded: 1901

Price Target and Rating

• Average Price Target for Harvard Bioscience: $2.00
• High Price Target: $2.00
• Low Price Target: $2.00
• Potential Upside/Downside: +313.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.30)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$12.40 million
• Net Margins: -64.68%
• Pretax Margin: -64.17%
• Return on Equity: -5.64%
• Return on Assets: -2.15%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.81
• Quick Ratio: 0.41

Sales & Book Value

• Annual Sales: $88.75 million
• Price / Sales: 0.24
• Cash Flow: $0.10 per share
• Price / Cash Flow: 4.80
• Book Value: $1.45 per share
• Price / Book: 0.33

Miscellaneous

• Outstanding Shares: 44,531,000
• Free Float: 40,301,000
• Market Cap: $21.52 million
• Optionable: Optionable
• Beta: 1.54